ABSTRACT
Objective To analyze the clinical treatment effect of traditional Chinese medicine and western medicine in the treatment of chronic obstructive pulmonary disease.Methods 160 patients with COPD from December 2014 to December 2016 in our hospital were enrolled in this study.and randomly divided into two groups.The control group was treated with western medicine only.The observation group was treated with traditional Chinese medicine and western medicine.The therapeutic effects of the two groups were compared.Results The effective rate was 88.75% in the observation group and 76.25% in the control group(P<0.05).After treatment, FEV1 was(1.85±0.42) L and FVC was(1.64±0.33) L in the observation group.In the control group, FEV1 was(2.56±0.35) L, FVC was(2.32±0.37) L, the improvement of the observation group was more obvious(P<0.05).The incidence of adverse reactions was 8.75% in the observation group and 7.50% in the control group, the difference was not statistically significant.Conclusion The clinical effect of traditional Chinese and western medicine in the treatment of COPD is remarkable and worthy of promotion.
ABSTRACT
Objective:To investigate the effect of gemcitabine on myeloid derived suppressor cells (MDSC) in the spleen of B lymphoma cell-bearing mice, and the therapeutic effect of gemcitabine combined with intratumoral injection of dendritic cells (DCs) in treatment of large B lymphoma. Methods: BALB/c mice were inoculated subcutaneously with B lymphoma A20 cells; large tumors were formed 30 d after inoculation. Gr-1~+ CD11b~+ MDSC proportion in the spleen was analyzed by flow cytometry before and after gemcitabine treatment. Splenic MDSC sorted by immunomagnetic beads was further treated with gemcitabine, and then the apoptosis of MDSC was examined by Annexin-V/PI staining. Tumor growth and survival time of A20 tumor-bearing mice were observed after treatment with gemcitabine and intratumoral injection of DCs. Results: Splenic Gr-1~+ CD11b~+ MDSC ratio in A20 cell-bearing mice was 10 times higher than that in the normal mice. Gemcitabine induced apoptosis and necrosis of purified MDSC in vitro in a time-dependent manner. The percentage of MDSC in the spleen of A20 tumor-bearing mice was decreased after injection of a single dose of gemcitabine. Gemcit-abine or intratumoral injection of DCs alone inhibited growth of tumor to a certain degree, with the mean survival periods of mice in the gemcitabine, DCs, and untreated groups being (48.8±3.6) d, (47.2±7.4) d, and (38.8±2.2) d, respectively. Gemcitabine chemotherapy combined with intratumoral DC injection resulted in continuous shrink of the tumors, and 60% of the mice survived for more than 90 d. Conclusion: Gemcitabine can effectively eliminate splenic MDSC in tumor-bearing mice. Gemcitabine chemotherapy and DCs immunotherapy can work synergistically in the treat-ment of huge lymphoma. These results provide an experimental basis for the comprehensive chemotherapy and immunotber-apy of relapsed or refractory lymphoma.